EN Mobile Logo

Search form



SGLT2 Inhibitors 2016: Year-End News Roundup

SGLT2 inhibitors made diabetes headlines this year by gaining FDA approval for cardiovascular indication. We highlight this news and more for 2016.

© Tetiana Yurchenko/Shutterstock.com


Cardiovascular risk/benefit profiles of pioglitazone and the SGLT2 inhibitor class are summarized, based on reports at ADA 2017.

A meta-analysis compared the renal side effects of SGLT2 inhibitors in patients with type 2 diabetes.

Our April list includes CV events with DPP-4 or SGLT2 inhibitors vs. insulin, and impact of obesity on nonalcoholic fatty liver disease and thyroid function.

Research has shown the beneficial effects of empagliflozin on all-cause and CV mortality. Does the same hold true for another SGLT2 inhibitor?

Our February list includes a newly approved drug combo, the ADA’s position statement on diabetic retinopathy, and lifestyle intervention studies.

Our February list includes updated guidelines for pediatric obesity, American Heart Assoc. statement on meal timing & frequency, and diabetes risks.

The risk of urinary tract infections (UTIs), but not necessarily genital infections, may vary by agent within the SGLT2 inhibitor class.


Subscribe to SGLT2 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.